FDA Restricts Use of 2 Monoclonal Antibody Treatments

Click here to read the full article.

The U.S. Food and Drug Administration (FDA) announced Jan. 24 it is restricting the use of two monoclonal antibody treatments for COVID-19, saying data show such treatments are “highly unlikely” to be active against the Omicron variant, currently the dominant strain in the country.

Monoclonal antibodies are laboratory-created proteins that mimic natural antibodies the body produces to fight off harmful pathogens, such as the CCP (Chinese Communist Party) virus, also known as the novel coronavirus.

The agency revised its emergency authorization for the two COVID-19 treatments that come from Regeneron and Eli Lilly. Their use is now limited to when the COVID-19 patient is “likely to have been infected with or exposed to a variant that is susceptible to these treatments.”

Continue reading here.

Scroll down for comments and share your thoughts!

Author

What do you think?

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

HUGE January Bedding Sale At MyPillow — Blankets, Quilts, Comforters 50% Off!

Trudeau not concerned over convoy, says 90 percent of truckers are vaccinated